Abivax SA American Depositary Shares (ABVX NASDAQ) stock market data APIs
$6.8778
0.28(4.1%)
as of May 1, 2025
Abivax SA American Depositary Shares Financial Data Overview
Prev. Close
6.8778
Open
7.1607
High
7.7729
Low
6.7389
52 wk Range
4.77-15.1
Market Cap
453 M
Shares Outstanding
63 419 K
Revenue
10 792 K
Beta
1.559
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Abivax SA American Depositary Shares data using free add-ons & libraries
Get Abivax SA American Depositary Shares Fundamental Data
{
"General": {
"Code": "ABVX",
"Type": "Common Stock",
"Name": "Abivax SA American Depositary Shares",
"Exchange": "NASDAQ",
"CurrencyCode": "USD",
"CurrencyName": "US Dollar",
"CurrencySymbol": "$",
"CountryName": "USA",
"CountryISO": "US",
"OpenFigi": "BBG01JLQNZ03",
"ISIN": null,
"CUSIP": null,
"CIK": "0001956827",
"EmployerIdNumber": null,
"FiscalYearEnd": "December",
"IPODate": "2023-10-20",
"InternationalDomestic": null,
"Sector": "Healthcare",
"Industry": "Biotechnology",
"HomeCategory": null,
"IsDelisted": false,
"Description": "ABIVAX Soci\u00e9t\u00e9 Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in P..."
}
}Abivax SA American Depositary Shares Fundamental data includes:
- Net Revenue: 10 792 K
- EBITDA: -171 883 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-12-31
- EPS/Forecast: -0.704
Get Abivax SA American Depositary Shares End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Abivax SA American Depositary Shares News
New
Abivax Reports Excellent One-Year Efficacy and Safety Data of ABX464 Phase 2b Maintenance Trial in Ulcerative Colitis
Interim analysis demonstrates best-in-class clinical remission in 55.3% of 217 ulcerative colitis (UC) patients (full analysis set) after 48 weeks of once-daily oral 50mg ABX464 Moreover, in the subgr...
Abivax Reports 2021 Financial Results and Operations Update
Feedback received from the US and European regulatory agencies, both supporting the advancement ABX464 into a phase 3 clinical program in ulcerative colitis (UC), final preparations for the launch of ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
